Shelton Capital Management’s Quest Diagnostics DGX Stock Holding History

Shelton Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,451	Closed	-$2.2M	–	812
2020 Q4	$2.2M	Hold	18,451	–	–	0.1%	194
2020 Q3	$2.11M	Hold	18,451	–	–	0.09%	250
2020 Q2	$2.1M	Buy	+18,451	New	+$1.96M	0.12%	174
2016 Q4	–	Sell	-2,468	Closed	-$209K	–	875
2016 Q3	$209K	Sell	2,468 -1,600	-39%	-$134K	0.02%	731
2016 Q2	$331K	Sell	4,068 -1,800	-31%	-$137K	0.03%	509
2016 Q1	$419K	Buy	+5,868	New	+$394K	0.04%	421

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Shelton Capital Management's DGX Position: Q1 2021 in Review

Shelton Capital Management sold out of Quest Diagnostics (DGX) in Q1 2021, closing a stake of 18,451 shares — an estimated $2.2M sold.

Shelton Capital Management first reported a position in DGX in Q1 2016 and held it in 6 quarters. The position peaked at $2.2M in Q4 2020. 817 funds tracked by Wall St. Rank hold DGX as of Q1 2021.

Shelton Capital Management reported no remaining Quest Diagnostics position as of Q1 2021 after selling out during the quarter.
Shelton Capital Management sold 18,451 Quest Diagnostics shares in Q1 2021, an estimated $2.2M.
Shelton Capital Management first reported a position in Quest Diagnostics in Q1 2016 and held it in 6 quarters.
Shelton Capital Management's Quest Diagnostics position peaked at $2.2M in Q4 2020.
817 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2021.

Based on Shelton Capital Management's 13F filing for Q1 2021, filed 14 May 2021.